Stem cell treatment for organ failure after aortic dissection surgery
Part of Heart & circulation, Injuries & trauma clinical trials.
This trial tests whether stem cell particles (called exosomes) can help people recover from multiple organ failure after emergency aortic dissection surgery. If you've had this surgery and your organs are struggling, this treatment might help them heal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had emergency surgery for a type A aortic dissection (a tear in the main artery).
- You are 60 years or older.
- Your organs are failing — specifically, at least two organs (like kidneys, lungs, or liver) are not working well.
- Your SOFA score (a measure of how many organs are failing) is 10 or higher.
- You do not have other severe health conditions, are not on long-term steroids, and your life expectancy is more than 4 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called sivelestat can help protect your organs after surgery for a type A aortic dissection. It may reduce inflammation and improve recovery.
This study tests whether giving special stem cells (called mesenchymal stem cells) can help improve poor graft function after a stem cell transplant. It aims to boost your blood cell counts so you recover better.
This trial tests whether exosomes from stem cells can help people whose peritoneal dialysis is no longer working well. It may improve fluid removal and reduce symptoms like swelling.
This study tests whether a special type of stem cell therapy (called mesenchymal stem cells) can help people with a severe liver condition called acute-on-chronic liver failure (ACLF). The goal is to see if this treatment can improve liver function and reduce the need for a liver transplant.
This trial tests whether a special type of stem cell therapy can help people with severe liver failure (called ACLF) that is not caused by a virus. The treatment may help your liver recover and improve your overall condition.
This trial tests whether an infusion of heart stem/progenitor cells can improve outcomes for children with a single working heart chamber (single ventricle) who are scheduled for the next surgical stage (Glenn or Fontan). It may help the heart function after surgery, but participation depends on several heart, lung, brain, and overall health safety criteria.
Hear when a new Multiple Organ Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.